Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02959164 · ClinicalTrials.gov registry record · Phase 1
Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
A Phase 1 study, sponsored by Mohammed Milhem.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02959164 is a Phase 1 study that has completed, run by Mohammed Milhem. The registered enrollment target is 36 participants.
The verdict
NCT02959164, a Phase 1 study, has completed, sponsored by Mohammed Milhem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this Phase 1b study is to assess the safety and maximum tolerated dose (MTD) of Decitabine in combination with Gemcitabine among previously treated patients diagnosed with advanced pancreatic adenocarcinoma or sarcoma (soft tissue and bone).
Interventions
- DRUG Decitabine
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-12-05 |
| Est. Completion | 2020-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02959164
The ClinicalTrials.gov registry entry for NCT02959164 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mohammed Milhem, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT02959164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02959164 about?
NCT02959164 is a clinical study titled "Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma". The purpose of this Phase 1b study is to assess the safety and maximum tolerated dose (MTD) of Decitabine in combination with Gemcitabine among previously treated patients diagnosed with advanced pancreatic adenocarcinoma or sarcoma (soft tissue and bone).
What is the current status of trial NCT02959164?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-12-05. Estimated completion is 2020-10-16.
What interventions are being tested in trial NCT02959164?
The interventions under investigation include: Decitabine (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT02959164?
This trial is sponsored by Mohammed Milhem, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.